Visit LathamDrive – A new site with resources to help emerging companies grow.

Miles P. Jennings

San Francisco
  • 505 Montgomery Street
  • Suite 2000
  • San Francisco, CA 94111-6538
  • USA

Miles P. Jennings represents public and private technology and life sciences companies as well as the underwriters and venture capitalists that transact with these companies.

Mr. Jennings advises these companies along their entire life cycle, from startup formation through growth and exit, including on private financing transactions, initial public offerings, and acquisitions.

His extensive transactional experience includes:

  • Venture capital financings
  • Initial public offerings and other public securities offerings
  • High yield debt offerings
  • Mergers and acquisitions
  • General company representation

Mr. Jennings is a key member of Latham’s Fintech Industry Group and is Co-Chair of the firm’s Global Blockchain and Cryptocurrency Task Force. He advises emerging companies and venture capital firms within the blockchain and cryptocurrency sector on matters involving financings, token rights and distributions, decentralized governance, and state and federal securities laws. Mr. Jennings acts as an outside advisor to ConsenSys’ Tachyon Accelerator Program.

Mr. Jennings is also a key member of Latham’s Healthcare & Life Sciences Industry Group, regularly advising companies within the sector on matters involving financings, public offerings, corporate governance, state and federal securities laws, fiduciary duties, employment and compensation, and Securities Exchange Act compliance and disclosure obligations.

Mr. Jennings received his JD, magna cum laude, from the Pepperdine University School of Law, where he was a fellow in the Palmer Center for Entrepreneurship & the Law. He received his BS in Mechanical Engineering from the University of California, Los Angeles.

Mr. Jennings’ technology and cryptocurrency representative work includes the following venture capital fund funds and emerging companies:

  • 3Box Labs
  • 8VC
  • Andreessen Horowitz
  • Ava Labs Inc.
  • Bitwise Asset Management
  • Capital Group
  • Connext
  • ConsenSys, ConsenSys Ventures, Tachyon Accelerator
  • Dragonfly Capital
  • Element Finance
  • Gala Games
  • Hippo Enterprises
  • Idle Labs
  • Kymeta
  • OPYN
  • Owl Ventures
  • Pantera
  • Paradigm
  • ParaFi
  • Pipedrive
  • Proterra
  • Ribbit Capital
  • Steel House
  • Tagomi
  • Token Foundry
  • Transak
  • Union Square Ventures
  • Uniswap

Mr. Jennings' life sciences and biotechnology representative work includes the following companies:

  • Aimmune Therapeutics
  • Angion Biomedica
  • Biomea Fusion
  • Clarify Health Solutions
  • Corvus Pharmaceuticals
  • CytomX Therapeutics
  • Halo Neuro
  • Hexagon Bio
  • InCarda Therapeutics
  • Insitro
  • Menlo Therapeutics
  • Mercator Medsystems
  • National Resilience
  • Satsuma Pharmaceuticals
  • Unity Biotechnology

Mr. Jennings also regularly advises investment banks on offerings for life sciences companies, including:

  • BofAMerrill Lynch
  • Citigroup, Inc.
  • Cowen and Company LLC
  • Credit Suisse
  • Goldman Sachs & Co.
  • Jefferies LLC
  • J.P. Morgan
  • Morgan Stanley
  • SVB Leerink Partners LLC
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.